Next Article in Journal
Autophagy as a Regulatory Component of Erythropoiesis
Next Article in Special Issue
Pharmacogenetics Informed Decision Making in Adolescent Psychiatric Treatment: A Clinical Case Report
Previous Article in Journal
Induced Pluripotent Stem Cells and Their Use in Cardiac and Neural Regenerative Medicine
Previous Article in Special Issue
Autism and Intellectual Disability Associated with Mitochondrial Disease and Hyperlactacidemia
Open AccessReview

The 15q11.2 BP1–BP2 Microdeletion Syndrome: A Review

Departments of Psychiatry & Behavioral Sciences, University of Kansas Medical Center, 3901 Rainbow Boulevard, MS 4015, Kansas City, KS 66160, USA
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Cesar Borlongan
Int. J. Mol. Sci. 2015, 16(2), 4068-4082; https://doi.org/10.3390/ijms16024068
Received: 5 January 2015 / Revised: 3 February 2015 / Accepted: 10 February 2015 / Published: 13 February 2015
Patients with the 15q11.2 BP1–BP2 microdeletion can present with developmental and language delay, neurobehavioral disturbances and psychiatric problems. Autism, seizures, schizophrenia and mild dysmorphic features are less commonly seen. The 15q11.2 BP1–BP2 microdeletion involving four genes (i.e., TUBGCP5, CYFIP1, NIPA1, NIPA2) is emerging as a recognized syndrome with a prevalence ranging from 0.57%–1.27% of patients presenting for microarray analysis which is a two to four fold increase compared with controls. Review of clinical features from about 200 individuals were grouped into five categories and included developmental (73%) and speech (67%) delays; dysmorphic ears (46%) and palatal anomalies (46%); writing (60%) and reading (57%) difficulties, memory problems (60%) and verbal IQ scores ≤75 (50%); general behavioral problems, unspecified (55%) and abnormal brain imaging (43%). Other clinical features noted but not considered as common were seizures/epilepsy (26%), autism spectrum disorder (27%), attention deficit disorder (ADD)/attention deficit hyperactivity disorder (ADHD) (35%), schizophrenia/paranoid psychosis (20%) and motor delay (42%). Not all individuals with the deletion are clinically affected, yet the collection of findings appear to share biological pathways and presumed genetic mechanisms. Neuropsychiatric and behavior disturbances and mild dysmorphic features are associated with genomic imbalances of the 15q11.2 BP1–BP2 region, including microdeletions, but with an apparent incomplete penetrance and variable expressivity. View Full-Text
Keywords: 15q11.2 BP1–BP2 microdeletion; Burnside-Butler syndrome; clinical and behavioral phenotype; chromosome breakpoints BP1 and BP2; Prader-Willi and Angelman syndromes; language and motor delays; autism; review 15q11.2 BP1–BP2 microdeletion; Burnside-Butler syndrome; clinical and behavioral phenotype; chromosome breakpoints BP1 and BP2; Prader-Willi and Angelman syndromes; language and motor delays; autism; review
Show Figures

Figure 1

MDPI and ACS Style

Cox, D.M.; Butler, M.G. The 15q11.2 BP1–BP2 Microdeletion Syndrome: A Review. Int. J. Mol. Sci. 2015, 16, 4068-4082.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop